Introduction
Mutational activation of the Ras/Raf/ERK signaling pathway is a frequent event in cancer. In this signaling pathway, upstream tyrosine kinases, Ras GTPases, and the Raf family of protein kinases are most frequently the direct targets of mutational activation. Less commonly, negative regulators such as Nf1 GAP, or downstream transcription factors such as Fos and Jun, are the targets of mutation. It is likely that mutational activation of this signaling pathway occurs in greater than 50% of all human cancers.
Oncogenic signaling by Ras GTPases relies on the activation of a set of effector proteins. The Raf protein kinase is activated by direct physical interaction with active Ras (van Aelst et al., 1993; Vojtek et al., 1993) , and genetic data argue strongly that, at least in fibroblasts and colon cancer cells, Raf is the dominant oncogenic effector of active Ras (Khosravi-Far et al., 1996; Marshall, 1996; Rajagopalan et al., 2002; Rangarajan et al., 2004) . Raf activation, either by mutation or by Ras activation, results in the sequential phosphorylation and activation of the MEK and ERK kinases, which are not themselves frequent targets of direct mutational activation. Activated ERK is implicated in a variety of biochemical functions, but it is likely that the oncogenic actions of ERK activity arise primarily through the activation of transcription factors. Among the transcription factors responsive to signaling through the Ras/Raf/ERK pathway, the transcription factor AP-1, composed of Fos-Jun dimers, is well characterized as a mediator of many of the oncogenic changes that arise through changes in gene expression (Wisdom, 1999; Mechta-Grigoriou et al., 2001) .
Cytokines of the TGF-b family mediate a wide array of biologic activities. TGF-b inhibits the proliferation of many epithelial cells, but in mesenchymal cells TGF-b can either inhibit or stimulate cell growth (Massague et al., 2000; Derynck and Zhang, 2003) . The role of TGF-b in tumorigenesis is complex. Several genes in the TGF-b signaling pathway have been shown to incur inactivating mutations in human cancers, including the type I and type II TGF-b receptor and the TGF-b responsive transcription factors Smad2 and Smad4 Parsons et al., 1995; Hahn et al., 1996 ; for a review, see Derynck and Zhang, 2003) . However, the proliferation and invasiveness of many cancer cells is increased by TGF-b, implying that autocrine production of TGF-b can actually promote tumor progression or invasion (Akhurst and . The mechanisms underlying the transcriptional response to TGF-b treatment are only partially understood. Smad2 and Smad3 are directly phosphorylated by the active type II TGF-b receptor (TGFBRII) (Shi and Massague, 2003) . Phosphorylation of Smad2 or Smad3 results in heterodimerization with Smad4 and translocation to the nucleus. Once in the nucleus, Smad proteins are able to form productive interactions with a number of transcription factors and other proteins that regulate gene expression. The transcription factor AP-1 is also essential for the activation of a number of genes whose expression is increased following TGF-b treatment of responsive cells (Keeton et al., 1991; Zhang et al., 1998) . While the mechanisms by which AP-1 participates in TGF-b-dependent gene expression are not clear, c-Jun has been shown to interact with Smad3 in a manner that supports activation of AP-1-dependent reporter genes (Zhang et al., 1998) . Thus, there is evidence to support the notion that both AP-1 and Smad proteins integrate the cellular response to TGF-b signals. The literature is also consistent with the idea that cell type is a central determinant of both the biologic and transcriptional response to TGF-b.
3T3 mouse fibroblasts undergo cell transformation in response to expression of oncogenes from the Ras/Raf/ ERK pathway. As many of the cellular changes that occur during cell transformation are dependent on changes in gene expression that occur at the level of transcription, gene expression profiling experiments have the potential to identify the transcriptional changes that underlie cell transformation. We have used gene expression profiling to identify the changes in gene expression that occur following transformation of 3T3 cells by Ras, Raf, and Fos, three oncogenes in the Ras/ Raf/ERK pathway. These experiments identified the downregulation of extracellular matrix (ECM) gene expression as a common target of oncogenic signaling through the Ras/Raf/ERK pathway, consistent with early studies that showed reduced ECM synthesis to be a prominent biochemical feature of fibroblast cell transformation. ECM synthesis in fibroblasts is known to be positively regulated by TGF-b. Here we show that both the changes in ECM gene expression and the transformed phenotype of 3T3 cells are substantially reversed by treatment with TGF-b. The results focus attention on ECM gene expression as a central regulator of the transformed phenotype, and the need to better understand the mechanistic basis of regulation of ECM synthesis.
Results

Gene expression changes in transformed 3T3 fibroblasts
The initial goal of this study was to define both the similarities and the differences in gene expression in cells that have been transformed by activated versions of genes in the Ras/Raf/ERK pathway. Toward this end, 3T3 cells were infected with recombinant retroviruses directing expression of activated versions of Ras, Raf, and Fos proteins. Polyclonal populations of transformed cells were isolated for each of the genes listed above. In every case, the resulting cells showed classic features of cell transformation, including refractile cell morphology, loss of contact inhibition with increased cell density at confluence, and anchorage independence ( Figure 1a and data not shown).
We used several different approaches to verify that the different oncogenes activated the ERK MAP kinase pathway as expected. We used antibodies specific for the Whole-cell extracts were prepared from 3T3, as well as Ras-, Raf-, and Fos-transformed 3T3, cells. The extracts were separated by SDS-PAGE and analysed by Western blotting for active, phospho-ERK, and total ERK. In addition, nuclear extracts were analysed for AP-1 DNA-binding activity by gel shift, and for activation of a synthetic AP-1 reporter gene (AP-1 Â 3-luciferase) ECM gene expression in fibroblast transformation R Wisdom et al phosphorylated, active form of the ERK to measure ERK activation. Consistent with the known mechanisms of action of these oncogenes, Ras-and Raftransformed fibroblasts showed strong activation of the ERK MAP kinase pathway, while Fos-transformed fibroblasts did not (Figure 1b) . The ERK activation in Ras-and Raf-transformed 3T3 cells resulted in an increase in AP-1 DNA-binding activity, and Fostransformed cells also showed an increase in AP-1 DNA-binding activity (Figure 1b ). Increased AP-1 DNA-binding activity was associated with an increase in the expression of a synthetic AP-1 reporter construct (AP-1 Â 3-luciferase). For both AP-1 DNA binding and AP-1-dependent gene activation, the rank order was Ras>Raf>Fos, demonstrating that Ras is the most potent activator of both ERK and AP-1 tested in these experiments ( Figure 1b) . Taken together, the results are consistent with the known mechanisms of action of these oncogenes. RNA isolated from 3T3 cells as well as the transformed cell derivatives was used to generate probes for gene expression profiling experiments. Probes corresponding to these RNAs were hybridized to a cDNA array representing about 8200 different genes. Genes that showed a greater than twofold change in each of the transformed cell types are listed in Table 1 .
Several features emerge from these gene expression profiles. First, more genes show a twofold increase in expression in Ras-transformed fibroblasts (77) than in either Raf-transformed (48) or Fos-transformed (46) cells. While this may be due to the ability of Ras to activate signaling pathways other than the ERK MAP kinase pathway, the increased activation of both ERK and AP-1 by Ras could also account for this result. In this regard, similar numbers of genes were repressed twofold or greater in each of these transformed cell types relative to 3T3 cells: 115, 101, and 114 in Ras-, Raf-, and Fos transformed cells, respectively. Second, in three-way comparisons, there is greater overlap among the genes that showed decreased levels of expression in transformed cells than among genes that show increased levels of expression. A total of 25 genes showed decreased expression in Ras-, Raf-, and Fos-transformed cells compared to 3T3 cells, while only 11 genes showed increased expression in all of the transformed cell derivatives. This result is similar to the conclusion of Ordway et al. (2004) , who demonstrated greater overlap in genes that are repressed during the transformation of 208F fibroblasts by Ras and Fos than genes that are induced by these oncogenes. Third, the list of genes that are repressed following cell transformation includes a number of genes that encode components of the ECM. While gene annotation methods make it difficult to determine accurately the fraction of genes that encode ECM components, whole genome analyses suggest this number is about 1%, far less than the 44% (11/25) detected in the repressed gene set (Waterston et al., 2002) . Furthermore, this result is consistent with a microarray analysis of Fos-expressing human fibroblasts, which identified many ECM genes, including Fibronectin, as targets of Fos repression (Scott et al., 2004) .
We validated the changes for 10 genes that showed increased expression and 10 genes that showed decreased expression in two different ways. First, Northern blots of the same RNA samples that were used in the microarray experiments were hybridized with labeled cDNA probes corresponding to the RNA of interest. Second, 3T3 cells were used to generate parallel pools of transformed cells, and RNA from these was collected and analysed by Northern blotting. In every case, the results of the Northern blots were consistent with the results of the microarray hybridization experiment; a subset of the Northern blot results is shown in Figure 2 .
The identity of the individual genes that are regulated during 3T3 cell transformation provides some insights into the molecular basis of transformation. Among the genes induced during transformation, several lines of evidence implicate the HMGA1 gene (also known as HMG-I(Y)) in oncogenesis. First, the HMGA1 gene is the target of recurrent chromosomal translocations in several different types of benign tumors, and can induce anchorage-independent growth of Rat-1a cells (Hess, 1998; Kazmierczak et al., 1999; Wood et al., 2000) . Second, it has functional properties, including the ability to regulate transcription, that are consistent with oncogenic potential. Third, pancreatic cancers, which are associated with an activating mutation of K-ras in nearly all cases, express uniformly high levels of HMGA1 (Abe et al., 2000) . Despite this, overexpression of HMGA1 in 3T3 cells did not result in either focus formation or growth of the cells in soft agar (data not shown). Therefore, while HMGA1 may contribute to the transformed phenotype, it is not sufficient to induce transformation of 3T3 cells.
Ras and TGF-b signaling mediate antagonistic effects on transcriptional control of ECM genes
Many of the genes that showed reduced expression relative to 3T3 cells encode proteins that are components of the ECM, including lysyl oxidase, OSF-2, fibronectin, and several collagen isoforms. The fact that this program of coordinate gene repression was conserved among the different oncogenes suggested that the repression of these genes might contribute significantly to the transformed phenotype. TGF-b is known to augment the production of ECM in fibroblasts, and a recent small-scale array analysis of TGF-b-dependent gene expression in human dermal fibroblasts suggested that genes that encode components of the ECM represent a significant fraction of the transcriptional response of fibroblasts to TGF-b (Verrecchia et al., 2001) . This suggested that TGF-b might function to reverse at least some of the oncogene-induced repression of expression.
As an initial test of the idea that oncogene-induced gene repression might be reversed by TGF-b treatment, we analysed the effect of TGF-b on the expression of the 10 genes most strongly repressed during Ras transformation of 3T3 cells by Northern blotting. The results showed that seven of these genes were in fact TGF-b inducible ( Figure 3 ; data not shown). This included six genes that encode components of the ECM, as well as one gene that encodes a follistatin-like molecule (AA242611) that may function in a negative feedback loop to regulate the efficiency of TGF-b signaling. In every case, genes that were induced by TGF-b in 3T3 cells were also induced by TGF-b treatment of transformed cells. In fact, although the levels of induced gene expression were highest in 3T3 cells, the fold induction was generally greater in the transformed cells, The results of these Northern blots strongly suggest that there is substantial overlap between the repression program elicited by Ras, Raf, and Fos and the panel of transcripts that are induced by TGF-b. In particular, TGF-b was able to reverse many of the changes in ECM gene expression that are characteristic of transformation. To obtain a global view of the degree of this overlap, we used gene expression profiling of 3T3 and Ras-transformed 3T3 cells, in the presence and absence of TGF-b treatment. Using the RNA samples described in Figure 3 , we generated probes for hybridization to an expanded array that contained about 10 000 different elements. In general, the genes that were differentially expressed in Ras transformed cells vs 3T3 cells were very similar between the two arrays. In 3T3 cells, 110 genes were induced twofold or more by 24 h of TGF-b treatment; in Ras transformed cells, 85 genes were induced to a similar degree. As can be seen in Table 2 , there is substantial overlap between these two sets of genes; 44 genes were induced twofold or greater by TGF-b treatment of both 3T3 cells and Ras-transformed fibroblasts. The gene expression profiles support several conclusions. First, about 3% of expressed genes (112 of 4628) were induced twofold or more by TGF-b treatment of 3T3 cells; in Ras-transformed cells, about 2.5% of expressed genes were induced twofold or more by TGF-b treatment.
Are genes induced by TGF-b repressed by Ras transformation at a global level? Of the 44 genes that were induced by TGF-b in both 3T3 cells and Rastransformed fibroblasts, 14 (32%) were repressed in Ras-transformed fibroblasts. This is far higher than the 3% level of overall gene repression by Ras, and demonstrates that Ras transformation does selectively result in repression of a subset of TGF-b-induced genes. Conversely, of the genes that were repressed by Ras transformation, 21% were induced by TGF-b treatment, again showing that the antagonistic regulation of gene expression by TGF-b treatment and Ras transformation are substantially higher than the level expected by chance. The genes that are induced twofold by TGFb and repressed twofold by Ras are listed in Table 3 ; consistent with the data shown in Figure 3 , a number of ECM genes are present in this list. In addition, several genes that encode components of the cytoskeleton are also subject to antagonistic regulation by Ras and TGFb; among these are smooth muscle alpha actin, transgelin, cardiac ankyrin repeat protein, and myosin light chain-2.
While antagonism of the TGF-b transcriptional response by Ras is substantial, it is not an invariant feature of Ras transformation. Most genes that are positively regulated by TGF-b are not antagonized by Ras. For example, Smad7, a negative regulator of Smad function which participates in negative feedback regula- tion of TGF-b signaling, is expressed to identical levels in 3T3 and Ras-transformed 3T3 cells, and is induced by TGF-b treatment in both cell types (Table 2) . Therefore, the ability of Ras to repress the levels of TGF-binducible genes is selective and confined to a subset of TGF-b-induced genes. The simplest interpretation of this result is that some aspects of TGF-b signaling remain, and are not altered by Ras transformation. Data presented below provide additional support for this interpretation.
Mechanisms of Ras repression of TGF-b induced gene expression
By what mechanisms might Ras transformation repress the expression of TGF-b-inducible genes?
One possibility is that Ras represses autocrine production of TGF-b. Two observations argue against this idea. First, ELISA measurements show that the levels of TGF-b1 and TGF-b2 in the supernatant of the different cell types are essentially identical; we were unable to detect expression of TGF-b3 at either the protein or mRNA level (data not shown). Second, the addition of large amounts of exogenous TGF-b does not result in expression of these ECM genes to the same levels in 3T3 and Ras-transformed fibroblasts (Figure 3 ), suggesting that factors other than TGF-b ligand availability are responsible for the repression. TGF-b initiates signaling by bringing together type I and type II TGF-b receptors. The serine/threonine kinase activity of both receptors is required for activity, and results in the phosphorylation of Smad2 and Smad3. These phosphorylations result in dissociation of Smad2/3 from the receptor, dimerization with Smad4, and translocation of the resulting Smad complexes into the nucleus, where the Smads can interact with other proteins and with DNA to regulate gene expression (Shi and Massague, 2003) . The reduced transcript levels of TGF-b-inducible genes in Ras-transformed cells is confined to a subset of genes, while other transcriptional targets of TGF-b signaling, such as Smad7, are not affected. This suggests that the early steps in TGF-b signaling are not controlled by Ras/Raf/ERK signaling. However, Kretzschmar et al. (1999) have previously shown that, in some epithelial cell types, ERK phosphorylation of Smad3 prevents Smad3 nuclear translocation in response to TGF-b treatment. To test this idea, we examined the ability of TGF-b to induce Smad translocation to the nucleus and to activate a Smad-binding element (SBE) reporter gene (SBE Â 4-luciferase). Addition of TGF-b to the media results in rapid translocation of Smad2 and Smad3 to the nucleus in both 3T3 cells and in Ras-transformed cells (Figure 4a ; data not shown). Furthermore, addition of TGF-b results in the activation of an SBE containing reporter gene in Ras-, Raf-, and Fos-transformed cells (Figure 4b ). The results demonstrate that early events in TGF-b signaling are not controlled by cellular transformation, and suggest that the transcriptional antagonism occurs at the level of gene-specific regulatory enhancer elements.
We also tested the ability of TGF-b to block signaling by the Ras pathway. Addition of TGF-b to the media did not significantly alter the levels of active, phosphorylated ERK, AP-1 DNA-binding activity, or the activity of AP-1-dependent reporter genes ( Figure 5) . Furthermore, endogenous genes that are activated by Ras/Raf/ERK signaling, such as HMGA1, were activated in the absence or presence of TGF-b (data not shown). Thus, the biochemical mechanisms that lead to gene activation by the Ras/ Raf/ERK pathway were not affected by TGF-b. As the mechanisms by which Ras, Raf, or Fos repress gene expression are not understood, it is difficult to carry out a direct test of the ability of TGF-b to regulate such a function. However, since TGF-b induces expression of (Figure 6a ). However, TGF-b treatment did alter the cell morphology, with substantial, but incomplete, reversion of the transformed morphologic changes. This was easily visualized by examining the increase in actin stress cable formation that was induced by TGF-b treatment. These changes were apparent within 24 h and maximal within 48 h of treatment with TGF-b. TGF-b treatment also led to a decrease in both the number and size of colonies that formed in soft agar; this effect was noticeable for both Ras and Raf, but was particularly strong in the case of Fos-transformed cells, in which soft agar colony formation was essentially completely blocked ( Figure 7 ). The results demonstrate that TGF-b treatment of transformed fibroblasts mediates substantial, although incomplete, reversion of the transformed phenotype. The ability of TGF-b to induce partial phenotypic reversion is consistent with previously published data showing that TGF-b can alter both actin stress fibers and anchorage-independent growth in Ras transformed fibroblasts as well as in epithelial cell (Moustakas and Stournaras, 1999; Bakin et al., 2004) . Whether this effect is due to the TGF-b-induced changes in ECM gene expression is not clear.
Discussion
Mutational activation of the ERK MAP kinase signaling pathway, including activating mutations in Ras and Raf, occurs in a very large fraction of human cancers. While our understanding of the molecular mechanisms underlying cell transformation is incomplete, it is clear that many of the phenotypic changes that occur are a consequence of changes in gene expression. We have used gene expression profiling to define the changes in gene expression that are induced by transforming oncogenes that function at different levels in a common biochemical pathway. Most descriptions of the changes in gene expression that occur during cell transformation have focused on the role of individual genes as potential mediators of transformation. By defining the overlapping gene expression patterns that are induced by oncogenes that function in a common biochemical pathway, we have identified coordinate repression of a large group of genes as a common feature of cell transformation by Ras, Raf, and Fos. Consistent with the idea that repression of gene expression is the most conserved aspect of the transcriptional response of fibroblasts, the gene expression profiles of Fos and Ras transformed 208F rat fibroblast cells also showed greater similarity in the targets of repressed, rather than activated, gene expression (Ordway et al., 2004) . Previous gene-profiling experiments have shown that DNMT1 expression is induced by Fos transformation, and that plasmid-driven expression of DNMT1 leads to both cell transformation and a similar program of gene repression (Bakin and Curran, 1999; Ordway et al., 2004) . Therefore, DNA methylation is a potential mechanism for generating the program of gene repression we observed. Of note, DNMT1 expression was not altered in any of the array analyses we performed; because of the multiple DNMTs present in the genome, this does not exclude methylation as a potential mechanism. Histone deacetylation has also been proposed to play a role in Fos-mediated gene repression, and to functionally promote cell invasion (McGarry et al., 2004) . The mechanisms by which Ras, Raf, and Fos would target methylation or histone deacetylation to specific genes are unknown. Analysis of the global patterns of gene expression during cellular transformation has the potential to identify genes that contribute to the defects that result in oncogenic transformation. One challenge in this effort is to understand how the changes in gene expression are integrated to generate cellular transformation. It is especially difficult to evaluate the contribution of individual genes to the transformed state in the setting of widespread changes in gene expression. In this regard, it is informative if groups of co-regulated genes have common biochemical mechanisms of action. Several of the genes that show reduced expression following cell transformation by Ras, Raf, or Fos encode components of the ECM, including lysyl oxidase, OSF-2, fibronectin, and various collagen isoforms. This coordinate regulation strongly suggests an important role for reduced ECM synthesis in generating the transformed state. Of note, others have shown that Fos transformation of human fibroblasts leads to reduced expression of lysyl oxidase and fibronectin, suggesting that ECM gene repression is a conserved feature of fibroblast transformation.
TGF-b antagonizes transformation-induced gene repression
Cytokines of the TGF-b family are well characterized for their ability to induce the synthesis of ECM; many of these changes have been observed to occur at the transcriptional level. Here we show that many, but not all, of the ECM genes that are repressed by oncogenic transformation are positively regulated by TGF-b. What biochemical mechanisms underlie the ability of TGF-b to reverse the conserved program of transformation-induced ECM gene repression? Our results show that Ras/Raf/Fos signaling does not affect either the levels of TGF-b that is synthesized or the early steps in TGF-b signaling, including Smad translocation to the nucleus and activation of a Smad reporter construct. Our data can be interpreted in the context of previous attempts to define the abilty of Ras signaling to alter the efficiency of signaling through the TGF-b. Previously published data in epithelial cells have indicated that ERK can inhibit the nuclear translocation of Smad proteins by direct phosphorylation of Smad2 and Smad3 (Kretzschmar et al., 1999) . However, the ability of TGF-b to elicit different responses in different cell types is well documented (for a review, see Derynck and Zhang, 2003) , and this mechanism has not been shown to apply in fibroblasts. Knockout data, as well as the analysis of tumor cells with loss-of-function mutations in Smad4, indicate that neither Smad3 nor Smad4 is required for TGF-b-dependent increases in ECM synthesis; given the central role of Smad4 in TGF-b signaling, this has been taken to indicate that the ability of TGF-b to promote ECM synthesis occurs by Smadindependent mechanisms (Hocevar et al., 1999; Sirard et al., 2000; Derynck and Zhang, 2003) .
The analysis of TGF-b-dependent gene expression in mammals, especially the plasminogen activator inhibitor-1 (PAI-1) gene, suggests that the transcription factor AP-1 may mediate some TGF-b-dependent transcriptional responses (Keeton et al., 1991; Zhang et al., 1998) . As AP-1 is also Ras-responsive, it is difficult to imagine how AP-1 could mediate both ECM gene repression in response to Ras and ECM gene induction in response to Furthermore, the gene expression data indicate that the ability of TGF-b to induce the expression of Ras-repressed gene is confined to a subset of these genes, largely including those that encode ECM components. Together, these observations suggest that oncogenic transformation and TGF-b counter-regulate ECM gene expression by controlling trans-acting factors other than Smads or AP-1. Further work will be required to identify such a factor, as well as to determine how it might serve to integrate signals from Ras/Raf/ERK and TGF-b signaling.
Regulation of the transformed phenotype by TGF-b in fibroblasts
The observation that TGF-b can reverse many of the transcriptional changes and phenotypic traits that are elicited by oncogenic transformation is broadly consistent with genetic evidence that many components of the TGF-b signaling pathway are tumor suppressors. Specifically, germline mutations in Smad4 are associated with juvenile polyposis syndromes, and tumor-associated mutations have been identified in type I and type II TGF-b receptors as well as in Smad2 and Smad4 Hahn et al., 1996; Howe et al., 1998; Takagi et al., 1998 ; for a review, see Derynck et al., 2001) . Furthermore, TGF-b is known to inhibit the proliferation of many cell types, especially epithelial cells. However, as yet there is no evidence that mutations in the TGF-b signaling pathway contribute to sarcomas, the tumor type that is presumably modeled by 3T3 fibroblast transformation. However, functional studies indicate that the follistatin-like molecule (also known as TSC-36) that we identified as a target of Ras repression and TGF-b activation plays a role in regulating the invasive phenotype of malignant fibroblasts (Johnson et al., 2000) . Recent reviews have stressed on the fact that many cancer cell types have retained partial TGF-b responsiveness (Lehmann et al., 2000; Akhurst and Derynck, 2001) . As the partial phenotypic reversion that is induced by TGF-b treatment of Ras-, Raf-, and Fostransformed 3T3 cells is accompanied by partial reversion of the gene expression changes, it is tempting to speculate that the two events are mechanistically linked. However, we have no data that directly support this notion, and it remains a possibility that the phenotypic changes are induced by other actions of TGF-b. In addition to regulation of ECM production, TGF-b regulates several other cellular processes that impact oncogenic transformation, including cell proliferation, cell fate determination, apoptosis, epithelialmesenchymal transformation, motility, and invasiveness (for a review, see Derynck and Zhang, 2003) . We have determined that TGF-b does not inhibit the proliferation of the transformed 3T3 cells used in this study, making direct effects on proliferation unlikely. The autocrine production of TGF-b by epithelial tumor cells is believed to promote ECM production by underlying stromal cells; this augmented ECM production then supports the continued proliferation of the tumor cells. In the case of fibroblastic cells, ECM production can be growth inhibitory; suggesting a possible role for the phenotypic reversion we have observed.
Our data focus attention on the regulation of ECM gene expression that occurs during tumorigenesis. Defining the molecular mechanisms by which transformation negatively regulates ECM production will help in establishing the molecular basis of the transformed phenotype in fibroblasts. In this regard, using TGF-b as a probe to reverse selected aspects of the transformed phenotype may be a useful tool. Further work will be required to define the role of the ECM in sarcoma development and progression.
Materials and methods
Cells and viruses
NIH 3T3 and the retroviral packaging cell line BOSC 23 were maintained in Dulbecco's minimal essential media supplemented with 10% FCS and antibiotics in 5% CO 2 . Infection with recombinant retroviruses was carried out as described previously . Briefly, 3T3 cells were infected with recombinant retroviruses expressing activated Ras (H-ras 61L), Raf (BXB-Raf), and Fos (FBR-Fos) from the vector pBABE-puro. Cells were then selected with puromycin 1.5 mg/ ml, and transformed cells were isolated. For gene expression studies, cells were maintained for 48 h in media containing 3% FCS to minimize activation of ERK signaling pathways. For TGF-b experiments, cells were also cultured in 3% FCS for 48 h; at this point, TGF-b (5 ng/mL, R and D Systems) was added.
RNA isolation, Northern blots, and microarray RNA was isolated using Promega RNA Isolation Reagents according to the manufacturer's specifications, and Northern blots were performed as described previously (Sprowles and Wisdom, 2003) . Double-stranded cDNA synthesis, biotinlabeled cRNA synthesis, and cRNA fragmentation were all conducted as described in the Affymetrix s GeneChip s expression analysis protocol. According to this protocol, first-strand synthesis of cDNA was performed using total RNA, a specialized oligo T7-(dT) 24 primer (Genset, San Diego, CA, USA), and Superscript (SSII) reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Second-strand synthesis was completed with T4 DNA polymerase, RNase H, and DNA ligase. Double-stranded cDNA was then cleaned by phenolchloroform extraction with Phase Lock Gels (Eppendorf, Westbury, NY, USA), ethanol precipitated, and resuspended in RNase-free water. Purified cDNA was then used as a template to develop biotin-labeled cRNA by in vitro transcription labeling with a HighYieldt BioArrayt RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA). Labeled cRNA was cleaned with RNeasy columns (Qiagen, Valencia, CA, USA) and fragmented to a length of bases. The quality of in vitro transcription and fragmentation products was assessed using the Agilent 2100 Bioanalyzer.
For the array analysis of transformed cell lines, a cDNA array of 9000 different mouse elements (Incyte) was hybridized with the probe as described below. For the studies using TGF-b, the probes were hybridized to Affymetrix U-74 oligonucleotide arrays, representing approximately 10 000 transcripts. Probes were hybridized at 451C overnight with 15 mg of fragmented, biotin-labeled cRNA, as defined in the Affymetrix expression analysis protocol. The hybridization buffer contained 100 mM MES, 1 M NaCl, 20 mM EDTA, 0.01% Tween 20, four eukaryotic hybridization controls (1.5 pM BioB, 5 pM BioC, 25 pM BioD, and 100 pM cre), 0.1 mg/ml herring sperm DNA (Promega, Madison, WI, USA), and 0.5 mg/ml of acetylated BSA. After hybridization, the arrays were washed and stained with an Affymetrix fluidics station following the Antibody Amplification Washing and Staining Protocol (Affymetrix, Santa Clara, CA, USA). Next, the arrays were scanned with an argon-ion laser at 570 nm, with a resolution of 3 mm/pixel (Affymetrix, Santa Clara, CA, USA). Probe intensities were calculated by splitting each oligonucleotide probe cell into 64 pixels (8 Â 8 pixels) and excluding bordering pixels. Raw probe intensities were then determined from the intensity distribution of the central pixels. To calculate background intensity, the entire array was divided into 16 sectors and the lowest 2% of intensity values were identified. Background was then defined as the average of these intensities. The background values were then deducted from the corresponding raw intensities before use. Within the arrays, each individual transcript is represented by perfect match probes in conjunction with a corresponding set of mismatch probes. A given transcript is called present if the average intensity value of perfect match cells is at least 1.5 times greater than the average intensity of mismatch cells, and the average intensity difference between perfect match and mismatch cells is at least four times the experimental noise. Poorly performing probes (probes in which the ratio between the average intensity of mismatch cells and perfect match cells is at least four times the experimental noise) were not included in the analysis. In order to compare expression among different arrays, the average intensity for each array was normalized by scaling to a target intensity value of 125. Nonchanging transcripts were identified as those that have a correlation coefficient greater than or equal to 0.95 across the experimental conditions used.
Antibodies, Western blots, and immunofluorescence
Antibodies were obtained from the Santa Cruz Biotechnology (Smad2, Smad3, and ERK), and Cell Signal (Phospho-ERK). Western blots were performed as described previously. For immunofluorescence, cells were plated on glass coverslips, treated as described, and fixed in 4% para-formaldehyde in PBS. Cells were stained with antibodies against Smad2 or Smad3, and detection was with Alexa-conjugated goat antirabbit antibodies. Cells were visualized on an Olympus BX61 microscope, and images were processed using Slidebook software.
